The First Peoples Hospital of Zhengzhou City

Zhengzhou, China

The First Peoples Hospital of Zhengzhou City

Zhengzhou, China
SEARCH FILTERS
Time filter
Source Type

Wang H.-D.,Zhengzhou University | Wang H.-D.,Xi'an Jiaotong University | Wu D.,Zhengzhou University | Feng Z.-Q.,The First Peoples Hospital of Zhengzhou city | And 10 more authors.
Electrophoresis | Year: 2014

The aim of this study was to investigate the genetic polymorphism of 20 short tandem repeat (STR) loci including D1S1656, D2S1338, D3S1358, D5S818, D6S1043, D7S820, D8S1179, D12S391, D13S317, D16S539, D18S51, D19S433, D21S11, CSF1PO, FGA, Penta D, Penta E, TH01, TPOX, and vWA in Han population of Henan, China and to assess its value in forensic science. Genomic DNA was extracted from 274 blood samples of unrelated healthy individuals in the Henan Han population. Alleles were amplified with PowerPlex® 21 system kit and PCR products were detected with ABI3130 genetic analyzer (Applied Biosystems) and the data were analyzed with modified PowerStats v1.2. A total of 229 alleles were observed in this Han population and the allelic frequencies ranged from 0.0020 to 0.5090 in the present study. Observed genotype distributions for each locus do not show deviations from Hardy-Weinberg equilibrium expectations (p < 0.05). The combined power of discrimination, combined power of exclusion, and combined matching probability of this 20 STR loci were 0.999999999, 0.999999994603, and 4.0433 × 10-24, respectively. The 20 STR loci are highly polymorphic in the Han population of Henan, China and they may be of great value in forensic science and human population genetics. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Li X.,Zhengzhou University | Wang S.,The First Peoples Hospital of Zhengzhou City | Ren H.,Zhengzhou University | Ma J.,Zhengzhou University | And 6 more authors.
Cancer Biology and Therapy | Year: 2016

Transmembrane tumor necrosis factor-α (tmTNF-α) is known to induce the activation of NF-κB to protect tumor cells. Upregulation of tmTNF-α leads to resistance to apoptosis and induces drug resistance in breast cancer. However, the expression of tmTNF-α in colorectal cancer (CRC) and its association with clinical outcome in CRC have remained unclear. In this study, we examined the tmTNF-α expression in CRC by immunohistochemistry and western blotting, assessed the prognostic value of tmTNF-α related to the recurrence/metastasis and survival of stage II/III CRC by the Kaplan-Meier survival curve and Cox regression model, and also explored the role of tmTNF-α expression on the chemotherapeutic efficacy of 5-Fluorouracil by flow cytometry assay and cell counting kit-8 (CCK-8) in vitro. Overall, we found that 77 (78.6%) out of 98 patients exhibited higher tmTNF-α expression in the CRC tissues comparing with the adjacent tissues. The tmTNF-α expression was correlated with Differentiation (P = 0.019), TNM stage (P = 0.039), Lymph nodes metastasis (P = 0.024) and Lymphovascular invasion (P = 0.027) but not related with Age (P = 0.617), Gender (P = 0.625), Tumor location (P = 0.138), Perforation/Obstruction (P = 1.000), Depth of invasion (P = 0.327), and microsatellite instability status (P = 0.150). The prognostic analyses showed that high tmTNF-α expression patients was significantly associated with decreased Disease-Free Survival (P = 0.0209) and Overall Survival (P = 0.0163). CCK-8 results suggested that the tmTNF-α influenced the chemotherapeutic effect of 5-Fluorouracil on colon cancer cells. Altogether, these data indicated the stageII/III CRC patients with high tmTNF-α expression were more likely to have a worse prognosis than patients with low tmTNF-α expression and tmTNF-α may influence the chemotherapeutic effect of 5-Fluorouracil. The mechanism for these observations warrants further study. © 2016 Taylor & Francis Group, LLC.


Ge J.-H.,The Peoples Hospital Of Zhengzhou | Zhang M.,The First Peoples Hospital Of Zhengzhou City | Feng S.-T.,The Peoples Hospital Of Zhengzhou
International Journal of Clinical and Experimental Medicine | Year: 2016

Objective: To investigate effect of HEPO genetically modified neural stem cell subarachnoid transplantation on functional recovery in rats with nerve injury. Methods: rats’ neural stem cells were cultured in vitro, while eukaryotic expression plasmid pcDNA3.1hEPO was established. They were transfected into neural stem cells and divided into three groups: cerebral infarction group, NSC s group, h EPO-NSC s group. Western blot was used to analysis h EPO protein expression in neural stem cells before and after transfection. 65 SD rats were selected. The middle cerebral artery occlusion (MCAQ) model was established. After successfully modeled, they were randomly divided into cerebral infarction groups, NSC s group, and h EPO-NSC s group with 20 in each group. After vein graft, fluorescence microscopy was used to observe the survival and distribution of CM-Di l labeled NSC. RT-PCR and Western Blot detection were used to detect AQP4 and AQP9 genetic changes and protein expression level in rats model with brain infarction; Before modeling, one day, three days, one week, two weeks, three weeks, four weeks after modeling, the modified (m NSS) neurological behavior scoring method was used to evaluate neurological function; the percentage of area use the to calculate infarct area; The rats were sacrificed under anesthesia condition, pathological changes of brain tissue were observed by HE staining; TUNEL assay was used to detect apoptosis. Results: Western blot results showed that human h EPO gene transfected neural stem cells were capable of expressing h EPO; RT-PCR and Western Blot test results showed that AQP4 and AQP9 gene and protein expression level in rats model with brain infarction in h EPO-NSC s group was significantly less than that in the NSC s group and the CI group with statistical significant difference (P < 0.05); m NSS neurobehavioral score showed in h EPO-NSC s group it was significantly lower than that in the NSC s group and cerebral infarction group with statistical significant difference (P < 0.05); Two weeks after transplantation, compared with and NSC s group and cerebral infarction group, cerebral infarction area and the edema in h EPO-NSC s group were reduced (P < 0.05); HE staining results showed that the cerebral tissue surrounded infiltration of inflammatory cells and edema had been significantly alleviated (P < 0.05); TUNEL assay showed that in EPO-NSC s group, the number of apoptotic cells was significantly less than the NSC s group and cerebral infarction group (P < 0.05). Conclusion: HEPO gene modified neural stem cells can reduce the expression of AQP4 and AQP9 gene and protein around the infarct zone, reduce the impact of neurological damage after cerebral infarction, reduce neuronal apoptosis, and promote the recovery of neurological function. © 2016, E-Century Publishing Corporation. All rights reserved.


Liu Y.,Zhengzhou University | Yue H.,The First Peoples Hospital Of Zhengzhou City | Xu S.,Zhengzhou University | Wang F.,Zhengzhou University | And 4 more authors.
International Journal of Clinical Oncology | Year: 2015

Background: Because of the poor prognosis of unresectable or metastatic hepatocellular carcinoma there is a need for effective systemic therapy. The purpose of this study was to assess the efficacy and safety of gemcitabine and oxaliplatin (GEMOX) combined with sorafenib, as first-line therapy, followed by sorafenib as maintenance therapy for patients with advanced hepatocellular carcinoma (HCC). Methods: In this open-label, multicenter, single-group, prospective study, eligible patients with advanced HCC received oral sorafenib 400 mg twice daily, gemcitabine 1,000 mg/m2 intravenously (i.v.) on day 1 and oxaliplatin 85 mg/m2 i.v. on day 2 every 14 days for up to six cycles. Patients without disease progression were then treated further with sorafenib as maintenance therapy until disease progression. Results: All forty-nine patients completed six cycles of combined GEMOX and sorafenib therapy. The objective response was 26.5 %. The median time to progression was 10.3 months (95 % CI: 8.7–11.9 months) and median overall survival was 15.7 months (95 % CI: 13.0–18.4 months). During the combination therapy, the most common grade 3/4 hematologic toxicity was neutropenia (22.4 %, 11/49 patients) and thrombocytopenia (14.3 %, 7/49 patients); grade 3/4 non-hematologic toxicity was fatigue (22.4 %, 11/49 patients) and appetite loss (18.4 %, 9/49 patients). During the maintenance therapy, grade 3/4 adverse events were nonhematologic toxicity, for example fatigue (16.0 %, 4/25 patients) and appetite loss (16.0 %, 4/25 patients). Conclusions: GEMOX combined with sorafenib as first-line therapy followed by sorafenib as maintenance therapy was effective with manageable toxicity for patients with advanced hepatocellular carcinoma. However, the results should be further validated in controlled phase II trials. © 2015, Japan Society of Clinical Oncology.


PubMed | Henan Provincial People Hospital, The First Peoples Hospital of Zhengzhou City and Zhengzhou University
Type: Clinical Study | Journal: International journal of clinical oncology | Year: 2015

Because of the poor prognosis of unresectable or metastatic hepatocellular carcinoma there is a need for effective systemic therapy. The purpose of this study was to assess the efficacy and safety of gemcitabine and oxaliplatin (GEMOX) combined with sorafenib, as first-line therapy, followed by sorafenib as maintenance therapy for patients with advanced hepatocellular carcinoma (HCC).In this open-label, multicenter, single-group, prospective study, eligible patients with advanced HCC received oral sorafenib 400 mg twice daily, gemcitabine 1,000 mg/m(2) intravenously (i.v.) on day 1 and oxaliplatin 85 mg/m(2) i.v. on day 2 every 14 days for up to six cycles. Patients without disease progression were then treated further with sorafenib as maintenance therapy until disease progression.All forty-nine patients completed six cycles of combined GEMOX and sorafenib therapy. The objective response was 26.5 %. The median time to progression was 10.3 months (95 % CI: 8.7-11.9 months) and median overall survival was 15.7 months (95 % CI: 13.0-18.4 months). During the combination therapy, the most common grade 3/4 hematologic toxicity was neutropenia (22.4 %, 11/49 patients) and thrombocytopenia (14.3 %, 7/49 patients); grade 3/4 non-hematologic toxicity was fatigue (22.4 %, 11/49 patients) and appetite loss (18.4 %, 9/49 patients). During the maintenance therapy, grade 3/4 adverse events were nonhematologic toxicity, for example fatigue (16.0 %, 4/25 patients) and appetite loss (16.0 %, 4/25 patients).GEMOX combined with sorafenib as first-line therapy followed by sorafenib as maintenance therapy was effective with manageable toxicity for patients with advanced hepatocellular carcinoma. However, the results should be further validated in controlled phase II trials.

Loading The First Peoples Hospital of Zhengzhou City collaborators
Loading The First Peoples Hospital of Zhengzhou City collaborators